After reading the scenario, respond to A, B, and C below. A. Referencing the scenario, describe the executive branch authority used by
the FDA in reclassifying insulin as a biologic and explain how this use of the
FSA's authority might affect the success of the Biologics Price Competition
and Innovation Act.
B. Referencing the scenario, explain how Congress could have addressed the
increasing cost of insulin prior to 2017.
C. Describe an informal power the president could use to influence the FDA's
decision to reclassify insulin as a biologic. Explain how the use of that
informal power relates to the principle of separation of powers.